Indacaterol

Indacaterol (INN) is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis.It was approved by the European Medicines Agency (EMA) under the trade name Onbrez on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. It needs to be taken only once a day, unlike the currently available formoterol and salmeterol.